Overall, the identification of recurrent deletions in RAD52 and HSD17B14 genes, along with previously described duplication in RAD51C, suggests that rare CNVs contribute to increased breast cancer risk, potentially in combination with other moderate-risk alleles as indicated by the identification of several double-mutants. This evidence concerns the gene RAD51C and breast carcinoma.